|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brambilla E, Travis WD, Colby TV, Corrin B
and Shimosato Y: The new World Health Organization classification
of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar
|
|
3
|
Lee HW, Kim EH and Oh MH:
Clinicopathologic implication of ezrin expression in non-small cell
lung cancer. Korean J Pathol. 46:470–477. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
von Lindern M, Fornerod M, van Baal S,
Jaegle M, de Wit T, Buijs A and Grosveld G: The translocation
(6;9), associated with a specific subtype of acute myeloid
leukemia, results in the fusion of two genes, dek and can, and the
expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell
Biol. 12:1687–1697. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wise-Draper TM, Mintz-Cole RA, Morris TA,
Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld
GC and Wells SI: Overexpression of the cellular DEK protein
promotes epithelial transformation in vitro and in vivo. Cancer
Res. 69:1792–1799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Privette Vinnedge LM, Ho SM,
Wikenheiser-Brokamp KA and Wells SI: The DEK oncogene is a target
of steroid hormone receptor signaling in breast cancer. PLoS One.
7:e469852012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cleary J, Sitwala KV, Khodadoust MS, Kwok
RP, Mor-Vaknin N, Cebrat M, Cole PA and Markovitz DM:
p300/CBP-associated factor drives DEK into interchromatin granule
clusters. J Biol Chem. 280:31760–31767. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khodadoust MS, Verhaegen M, Kappes F,
Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz
DM and Soengas MS: Melanoma proliferation and chemoresistance
controlled by the DEK oncogene. Cancer Res. 69:6405–6413. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Privette Vinnedge LM, McClaine R, Wagh PK,
Wikenheiser-Brokamp KA, Waltz SE and Wells SI: The human DEK
oncogene stimulates β-catenin signaling, invasion and mammosphere
formation in breast cancer. Oncogene. 30:2741–2752. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hasiów-Jaroszewska B, Borodynko N and
Pospieszny H: Infectious RNA transcripts derived from cloned cDNA
of a pepino mosaic virus isolate. Arch Virol. 154:853–856. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin
R and Lin Z: Clinicopathological significance of DEK overexpression
in serous ovarian tumors. Pathol Int. 59:443–447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu Q, Li Z, Lin H, Han L, Liu S and Lin Z:
DEK overexpression in uterine cervical cancers. Pathol Int.
58:378–382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y,
Li J and Lin Z: DEK over expression as an independent biomarker for
poor prognosis in colorectal cancer. BMC Cancer. 13:3662013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu S, Wang X, Sun F, Kong J, Li Z and Lin
Z: DEK overexpression is correlated with the clinical features of
breast cancer. Pathol Int. 62:176–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wrona A and Jassem J: The new TNM
classification in lung cancer. Pneumonol Alergol Pol. 78:407–417.
2010.In Polish.
|
|
16
|
Kappes F, Burger K, Baack M, Fackelmayer
FO and Gruss C: Subcellular localization of the human
proto-oncogene protein DEK. J Biol Chem. 276:26317–26323. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kappes F, Scholten I, Richter N, Gruss C
and Waldmann T: Functional domains of the ubiquitous chromatin
protein DEK. Mol Cell Biol. 24:6000–6010. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alexiadis V, Waldmann T, Andersen J, Mann
M, Knippers R and Gruss C: The protein encoded by the
proto-oncogene DEK changes the topology of chromatin and reduces
the efficiency of DNA replication in a chromatin-specific manner.
Genes Dev. 14:1308–1312. 2000.PubMed/NCBI
|
|
19
|
Campillos M, García MA, Valdivieso F and
Vázquez J: Transcriptional activation by AP-2alpha is modulated by
the oncogene DEK. Nucleic Acids Res. 31:1571–1575. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Soares LM, Zanier K, Mackereth C, Sattler
M and Valcárcel J: Intron removal requires proofreading of U2AF/3′
splice site recognition by DEK. Science. 312:1961–1965. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kavanaugh GM, Wise-Draper TM, Morreale RJ,
Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF,
Wells JM, et al: The human DEK oncogene regulates DNA damage
response signaling and repair. Nucleic Acids Res. 39:7465–7476.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carro MS, Spiga FM, Quarto M, Di Ninni V,
Volorio S, Alcalay M and Müller H: DEK Expression is controlled by
E2F and deregulated in diverse tumor types. Cell Cycle.
5:1202–1207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Casas S, Nagy B, Elonen E, Aventín A,
Larramendy ML, Sierra J, Ruutu T and Knuutila S: Aberrant
expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia.
Leuk Lymphoma. 44:1935–1941. 2003. View Article : Google Scholar
|
|
24
|
Kroes RA, Jastrow A, McLone MG, Yamamoto
H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma
J, et al: The identification of novel therapeutic targets for the
treatment of malignant brain tumors. Cancer Lett. 156:191–198.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kappes F, Khodadoust MS, Yu L, Kim DS,
Fullen DR, Markovitz DM and Ma L: DEK expression in melanocytic
lesions. Hum Pathol. 42:932–938. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu K, Feng T, Liu J, Zhong M and Zhang S:
Silencing of the DEK gene induces apoptosis and senescence in CaSki
cervical carcinoma cells via the up-regulation of NF-κB p65. Biosci
Rep. 32:323–332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Paderova J, Orlic-Milacic M, Yoshimoto M,
da Cunha Santos G, Gallie B and Squire JA: Novel 6p rearrangements
and recurrent translocation breakpoints in retinoblastoma cell
lines identified by spectral karyotyping and mBAND analyses. Cancer
Genet Cytogenet. 179:102–111. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Privette Vinnedge LM, Kappes F, Nassar N
and Wells SI: Stacking the DEK: From chromatin topology to cancer
stem cells. Cell Cycle. 12:51–66. 2013. View Article : Google Scholar :
|
|
29
|
Lin L, Piao J, Ma Y, Jin T, Quan C, Kong
J, Li Y and Lin Z: Mechanisms underlying cancer growth and
apoptosis by DEK overexpression in colorectal cancer. PLoS One.
9:e1112602014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Datta A, Adelson ME, Mogilevkin Y,
Mordechai E, Sidi AA and Trama JP: Oncoprotein DEK as a tissue and
urinary biomarker for bladder cancer. BMC Cancer. 11:2342011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang J, Sun L, Yang M, Luo W, Gao Y, Liu
Z, Qiu X and Wang E: DEK depletion negatively regulates
Rho/ROCK/MLC pathway in non-small cell lung cancer. J Histochem
Cytochem. 61:510–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kappes F, Damoc C, Knippers R, Przybylski
M, Pinna LA and Gruss C: Phosphorylation by protein kinase CK2
changes the DNA binding properties of the human chromatin protein
DEK. Mol Cell Biol. 24:6011–6020. 2004. View Article : Google Scholar : PubMed/NCBI
|
